Laurie S. Anderson
1
* , PharmD ;
Heidi G Bell
2
* , RPh, MD ;
Michael Gilbert
3
, MPH ;
Julie E Davidson
4
, MPH, PhD ;
Christina Winter
4
, MD ;
Monica J Barratt
5, 6, 7
, PhD ;
Beta Win
4
, MSc ;
Jeffery L Painter
1
, JD ;
Christopher Menone
3
, MESc ;
Jonathan Sayegh
7
, JD ;
Nabarun Dasgupta
3
, MPH, PhD
1
GlaxoSmithKline, Research Triangle Park, NC, United States
2
Gyra MediPharm Consulting, Research Triangle Park, NC, United States
3
Epidemico, Inc, Boston, MA, United States
4
GlaxoSmithKline, Stockley Park, Middlesex, United Kingdom
5
National Drug and Alcohol Research Centre, UNSW Australia, Randwick, Australia
6
Bluelight.org, Dover, DE, United States
7
Kadiant Analytics, Boston, MA, United States
*these authors contributed equally
Corresponding Author:
-
Laurie S. Anderson, PharmD
-
GlaxoSmithKline
-
5 Moore Drive
-
PO Box 13398
-
Research Triangle Park, NC 27709-3398
-
United States
-
Phone:
1 919 475 0747
-
Fax: 1 000-000-0000
-
Email: laurie.s.anderson@gsk.com